Arcturus Therapeutics (ARCT) Short Interest Analysis
Recent data indicates that Arcturus Therapeutics (ARCT) remains a heavily shorted equity, with short interest currently sitting at 19.2% of shares outstanding. As of the September 15, 2026, settlement date, the total short position stands at 5.5 million shares. While this represents a slight reduction from the 21.5% level observed in the prior reporting period, the stock remains in the top 7% of the 5,955 names tracked by our analytics.
Liquidity and Squeeze Risk
The days-to-cover ratio is currently elevated at 6.4, suggesting that any sudden positive catalyst could force a rapid covering cycle. Despite the recent trend of shorts trimming their positions over three consecutive settlement periods, the high percentage of float held short continues to provide a structural floor for volatility. Investors should monitor the borrow fee, which is currently holding at a modest 0.4%, indicating that while the position is large, the immediate cost of carry remains manageable for institutional shorts.
Signal data sourced from CurvedTrading. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.